ClinicalTrials.gg
Not yet recruitingNCT06956807CARDIOMESH IIUpdated May 4, 2025

Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells

A Phase 1 interventional study of VB-C01 cellularised patch in CABG-patients, Heart Failure and Myocardial Infarction (MI), sponsored by Viscofan. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by Viscofan · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 275 studies in Heart Failure with a site in Poland — 57 open to participants now, 75 under way, 20 of them phase 3. Heart Failure · Poland.

Planned enrollment
216th of 225
10 · median 300
Started
2025
with 12 others
Phase 1
8 of 275
1 open now
Primary completion
2026-12
later than 26 of 74 live
Registered
249th of 275
by date

Among the 275 studies in Heart Failure with a site in Poland, this one is the 216th largest by planned enrollment of the 225 interventional ones that give a count, is one of 13 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 26 of the 74 other live ones, and was the 249th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

57 of the 275 studies in Heart Failure with a site in Poland are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Heart Failure with a site in Poland, or all of them as a file.
02

Study summary

  • The Cardiomesh II clinical trial is a phase I open label study intended to enrol 10 patients to evaluate the safety and efficacy of surgical epicardial implantation of a membrane seeded with allogeneic adipose tissue derived stem cells in patients scheduled to undergo coronary revascularisation surgery and at high risk of developing heart failure.
  • The primary objective of the study is to evaluate the safety of surgical implantation of this membrane in patients with large ischaemic myocardial scars scheduled to undergo coronary revascularisation surgery. The secondary objective is to investigate the efficacy of the above treatment in terms of reduction of scar size and ventricular function parameters.
Read the detailed description
  • The clinical trial CARDIOMESH II aims to attenuate adverse remodelling of the left ventricle, which is the main cause of death in ischaemic heart disease, through the development of a new regenerative therapy consisting of the combination of allogeneic adipose derived stem cells with bovine derived collagen membranes to promote repair of damaged myocardium. This is predicted to achieve a 10% reduction in mortality related to ischaemic heart failure.
  • Specifically, the working hypotheses of the project are:
  • Surgical implantation of a membrane containing allogeneic adipose derived stem cells in patients with large myocardial scars scheduled to undergo coronary revascularisation surgery is technically feasible.
  • Surgical implantation of a membrane containing allogeneic adipose derived stem cells in patients with large myocardial scars scheduled to undergo coronary revascularisation surgery is safe in terms of the primary objective consisting of major adverse cardiac and cerebrovascular events (MACCEs).
  • Surgical implantation of the aforementioned bioengineering product is safe in terms of cardiac effects and immunological analysis.
  • Surgical implantation of this cellularised membrane shows beneficial effects in terms of efficacy measured by surrogate cardiac imaging parameters.
  • Designed as an international phase I clinical trial to be conducted at two sites in two European countries, the purpose of the study is to establish the basic safety parameters and to obtain preliminary efficacy data on clearly established surrogate variables to undertake future larger scale trials focused on clinical efficacy.
03

Conditions studied

  • CABG-patients
  • Heart Failure
  • Myocardial Infarction (MI)

Keywords

  • heart failure
  • coronary revascularisation surgery
  • adipose-derived stem cells
  • myocardial infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients planning to undergo coronary revascularisation surgery within one month of study entry.
  2. ≤45% by CMRI.
  3. History of myocardial infarction at least 3 months prior to inclusion.
  4. Scar covering at least 15% of the total left ventricular myocardial mass defined by late enhancement on CMRI.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another clinical trial within 30 days prior to inclusion.
  2. Prior treatment with cell or gene therapy.
  3. Be a candidate for heart transplant at the time of study entry.
  4. Diagnosis of acute myocardial infarction with 3 months prior to inclusion.
  5. Need for urgent revascularisation surgery.
  6. Strict for the use of CMRI (pacemaker or implantable automatic defibrillator carriers, previous reactions to gadolinium contrast, claustrophobia, cochlear implants, etc.).
  7. Presence of uncontrolled ventricular arrhythmias (ventricular tachycardia or ventricular fibrillation) at the time of implant surgery.
  8. Active systemic infection.
  9. Women who are pregnant or breastfeeding.
  10. Mental disease or psychological condition that impedes the subject from understanding the nature of the protocol and granting his/her consent
  11. Advanced dementia according to the Barthel index.
  12. History of primary or acquired immunodeficiency or on therapy (within 3 months prior to inclusion or if the need for immunotherapy is foreseeable at any time during the study follow up).
  13. Tumour disease, except that eradicated at least 5 years prior to inclusion in the study and without receiving chest radiotherapy. Completely eradicated non melanoma skin tumours (at any time) not requiring chest chemotherapy or radiotherapy are permitted.
  14. History of disease.
  15. Stroke within 12 months prior to inclusion.
  16. Respiratory compromise or need for home oxygen therapy.
  17. of less than 1 year for any reason
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Treatment with VB-C01

    Treatment arm in which patients will be treated with a VB-C01 cellularised patch.

    Combination Product: VB-C01 cellularised patch

Interventions

  • Combination productVB-C01 cellularised patch

    surgical epicardial implantation of a membrane seeded with allogeneic adipose tissue derived stem cells in patients scheduled to undergo coronary revascularisation surgery and at high risk of developing heart failure

06

What researchers measure

Primary outcomes

  1. combination of MACCEs at all follow up visits during the first year after treatment

    combination of MACCEs at all follow up visits during the first year after treatment (after surgery, at 1, 3, 6, 9 and 12 months). MACCEs are defined as all cause death, myocardial infarction requiring target vessel revascularisation, hospitalisation for heart failure, cardiac tamponade or pericardial constriction, sustained ventricular tachycardia, ventricular fibrillation, and stroke.

    Time frame: 12 months

Secondary outcomes

  1. Safety - Composite MACCE

    Composite MACCE (all cause death, myocardial infarction requiring target vessel revascularisation, hospitalisation for heart failure, cardiac tamponade or pericardial constriction, sustained ventricular tachycardia, ventricular fibrillation, and stroke) at all follow up visits during the first year after treatment (after surgery, 1, 3, 6, 9 and 12 months),

    Time frame: 12 months

  2. Safety - Hematology parameters

    Erythrocytes, Haemoglobin, Haematocrit, Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, Prothrombin time, APTT, INR. Measurement of the values and evaluation of their clinical significance in case they are outside of the normal range.

    Time frame: 12 months

  3. Safety - Adverse Events

    Any cause adverse event at all follow up visits during the first year after treatment (after surgery, 1, 3, 6, 9 and 12 months)

    Time frame: 12 months

  4. Safety - Biochemical blood parameters

    Measurement of biochemistry paramenters in blood including Glucose, Creatinine, Urea, GOT, GPT, GGT, Total bilirubin, Alkaline phosphatase, Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, Total proteins, Sodium, Potassium, Calcium, Chloride. Evaluation of clinical significance in case values are out of normal range.

    Time frame: 12 months

  5. Safety - New York Heart Association (NYHA) functional class

    Assessment of the New York Heart Association (NYHA) functional class before surgery (the first assessment will be done during the screening process and repeated before the procedure), at 6 and 12 months after surgery.

    Time frame: 12 months

  6. Safety - Minnesota Living with Heart Failure (MLHFQ) questionnaire

    Minnesota Living with Heart Failure (MLHFQ) questionnaire, before surgery (the first assessment will be done during the screening process, at least one day before surgery), at 6 and 12 months after surgery.

    Time frame: 12 months

  7. Safety - 6 minute walk test

    The 6 minute walk test will be performed before surgery (the first assessment will be done during the screening process, at least one day before surgery), at 6 and 12 months after surgery.

    Time frame: 12 months

  8. Safety - Brain natriuretic peptide curve (Nt proBNP or BNP)

    Brain natriuretic peptide curve (Nt proBNP or BNP, depending on the availability at each site using the same parameter throughout the follow up of each patient). Levels will be measured during the screening process (the first assessment will be done, at least one day before surgery), on the second day after surgery and at 6 and 12 months after product administration.

    Time frame: 12 months

  9. Safety - C reactive protein (CRP) levels

    C reactive protein (CRP) levels will be assessed prior to surgery (the first assessment will be done during the screening process, repeated prior to surgery), at hospital discharge, and 1 month after product administration.

    Time frame: 1 month

  10. Safety - Incidence of subacute pericardial inflammation or constrictive physiology

    Incidence of subacute pericardial inflammation or constrictive physiology as assessed by echocardiography and cardiac magnetic resonance imaging (CMRI) at months 1, 6 and 12 after treatment. The first assessment will be done during the screening process.

    Time frame: 12 months

  11. Safety - Immunological analysis

    The following immunological analysis will be performed: B Lymphocytes, NK Lymphocytes (CD16+), T Lymphocytes (CD3+), Th Lymphocytes (CD4+), Activated Th Lymphocytes (CD4+DR+), Treg Lymphocytes (CD4+CD25+), Treg Lymphocytes (CD4+CD25+), Activated Treg Lymphocytes (CD4+CD25+DR+), Cytotoxic T Lymphocytes (CD8+), Activated Cytotoxic T Lymphocytes (CD8+DR+), Cytotoxic Treg Lymphocytes (CD8+CD25+), Activated Cytotoxic Treg Lymphocytes (CD8+CD25+DR+), Albumin, Alpha globulin, Beta globulin, Gamma globulin, IgG, IgM and anti-HLA antibodies (the first assessment will be done during the screening process) at discharge (at discharge excluding Serum Cytokines and anti-HLA antibodies) and 1 month after product administration.

    Time frame: 1 month

  12. Efficacy - Change in scar size

    Absolute change in scar size expressed as percentage of left ventricular mass (i.e. scar mass corrected for total left ventricular mass), absolute change in percentage of viable left ventricular mass (i.e. viable mass corrected for total left ventricular mass), absolute change in total scar size (expressed in grams), and absolute change in viable mass (expressed in grams).

    Time frame: 12 months

  13. Efficacy - end systolic volume

    Biomechanical parameters of the left ventricle: end systolic volume, end diastolic volume, ejection fraction, segmental contractility, and segmental wall thickness. All values will be obtained by CMRI analysis.

    Time frame: 12 months

  14. Efficacy - end diastolic volume

    Biomechanical parameters of the left ventricle: end systolic volume, end diastolic volume, ejection fraction, segmental contractility, and segmental wall thickness. All values will be obtained by CMRI analysis.

    Time frame: 12 months

  15. Efficacy - ejection fraction

    Biomechanical parameters of the left ventricle: end systolic volume, end diastolic volume, ejection fraction, segmental contractility, and segmental wall thickness. All values will be obtained by CMRI analysis.

    Time frame: 12 months

  16. Efficacy - segmental contractility

    Biomechanical parameters of the left ventricle: end systolic volume, end diastolic volume, ejection fraction, segmental contractility, and segmental wall thickness. All values will be obtained by CMRI analysis.

    Time frame: 12 months

  17. Efficacy - segmental wall thickness

    Biomechanical parameters of the left ventricle: end systolic volume, end diastolic volume, ejection fraction, segmental contractility, and segmental wall thickness. All values will be obtained by CMRI analysis.

    Time frame: 12 months

07

Study locations

1 site
  • Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach
    Katowice - Ochojec, 40-635, Poland
    • Radoslaw Gocol, MD · Contactkkch@sum.edu.pl · +48 32 3598877
    • Kowalowka Adam, MD · Contactkkch@sum.edu.pl · +48 32 3598877
    • Radoslaw Gocol, MD · Principal investigator
    • Adam Kowalowka, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's planned 15 months is above that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
May 4, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
May 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06956807
Lead sponsor
Viscofan
Collaborators
KCRI Sp. z o.o., Medical University of Silesia, Clinica Universidad de Navarra, Universidad de Navarra, Hospital General Universitario Gregorio Marañon
Responsible party
Sponsor
First posted
May 4, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 4, 2025

Study contacts

Lluis Quintana, PhD, MBA
Contact
quintana@bio.viscofan.com
+49 6201 86-236
Jesus Izco, PhD
Contact
IzcoJ@viscofan.com
+34948198444
Radoslaw Gocol, MD
study chair · Medical University of Silesia
Javier Bermejo, MD
principal investigator · Hospital General Universitario Gregorio Marañón

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion